| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 340.44 | 6.9% |
| Total Income | 352.67 | 6.3% |
| Expenditure | 205.46 | 3.2% |
| PBT | 147.21 | 11.1% |
| Net Profit | 110.09 | 11.2% |
| OPM | 41.11% | 5.15pp |
| NPM | 31.22% | 1.37pp |
| EPS | 6.35 | 11.2% |
Blue Jet Healthcare Announces Q4 & FY25 Results: Highest Q4 Revenue at Rs. 3,404 mn; a jump of 85.1% YoY
14 May 2025 · 14 May 2025, 05:52 pm
Summary
Blue Jet Healthcare Limited (BLUEJET) reported financial results for the quarter and year ended March 31, 2025. The company saw a significant increase in revenue, EBITDA, and PAT for both Q4 and FY25. The growth was mainly led by the Pharmaceutical Intermediate & API Business.
Key Highlights
- 1
Revenue from operations for Q4 FY25 stood at Rs. 3,404 mn
- 2
Revenue growth is mainly driven by higher sales in Pharmaceutical Intermediate in Q4 FY25
- 3
Highest ever EBITDA for the quarter came at Rs. 1,400 mn
- 4
EBITDA margin for the quarter came at 41.1%
- 5
PAT for the quarter was at Rs. 1,101 mn
- 6
PAT margin for the quarter came at 32.3%
- 7
Revenue from operations for FY25 stood at Rs. 10,300 mn
- 8
Revenue growth is mainly driven by higher sales in Pharmaceutical Intermediate in FY25
- 9
EBITDA for FY25 came at Rs. 3,777 mn
- 10
EBITDA margin for FY25 was at 36.7%
- 11
PAT for FY25 stands at Rs. 3,052 mn
- 12
PAT margin for FY25 was at 29.6%
- 13
Fund Raising approval in the form of QIP, Preferential Issue, Private Placement and / or any other method approved by board for Rs. Rs. 15,000 Mn
- 14
Gadolinium based Contrast Media Intermediate products have been commercialised and the company has started dispatching them in Q4 FY25
- 15
Final dividend of Rs. 1.2 per share of face value of Rs. 2 each for the year ended March 31, 2025
- 16
30,366.32 sq. mts of plot allotted to Blue Jet Healthcare located at Dahej Ill, Industrial Estate Gujarat Area, GIDC for a consideration of Rs. 11.12 cr.
- 17
Demand notice has been received under Section 156 of the Income Tax Act, 1961 amounting to Rs. 1,933.86 million
Management Comments
Mr. Shiven Arora
Managing Director, Blue Jet Healthcare Limited
Blue Jet has performed exceptionally well in the Q4 and FY25 as a whole. We take pride in informing that the company clocked a revenue of Rs. 10,300 Mn with 44.7% growth Yoy with highest ever EBITDA achieved of Rs. 3,777 Mn for the year. For the quarter, the revenue stood at Rs. 3,404 and EBITDA at Rs. 1,400 Mn. The staggering growth showcases our efforts in operational efficiencies and strong business foundation. This growth was mainly led by the Pharmaceutical Intermediate & API Business. The Board of directors have proposed a dividend of Rs. 1.2 per share for the year subject to the approval of shareholders. | am delighted to share that the Gadolinium based Intermediate products have been commercialised and the company has started dispatching them in this quarter. We have also been allotted a plot of 30,366 sq. mts. at Dahej Ill, Industrial Estate Gujarat Area, GIDC for a consideration of Rs. 11.12 cr. With multiple industry tailwinds and a strong vision, we look forward to a good year ahead amidst the global challenges.
Informational and educational content only. Not investment advice.